| Chronic Myelogenous Leukemia |
1 |
1 |
| Biologic Therapy |
0 |
0.86 |
| Patient Safety |
0 |
0.7 |
| Remission |
0 |
0.56 |
| Adverse Effects |
0 |
0.5 |
| Antineoplastic Drug |
0 |
0.4 |
| White Blood Cell Count |
0 |
0.35 |
| Cancer |
0 |
0.33 |
| Stem Cell Research and Therapy |
0 |
0.33 |
| Care and Maintenance of Vision |
0 |
0.3 |
| Blood |
0 |
0.28 |
| Bone Marrow Transplant |
0 |
0.28 |
| Tyrosine Kinase Inhibitor |
0 |
0.25 |
| Transplantation |
0 |
0.22 |
| Tobacco Cessation |
0 |
0.19 |
| Acute Leukemia |
0 |
0.17 |
| Clinical Guidelines |
0 |
0.17 |
| Bone Marrow |
0 |
0.16 |
| CT Scan |
0 |
0.13 |
| Revenue and Practice Management |
0 |
0.12 |
| Bone |
0 |
0.11 |
| Fatigue |
0 |
0.11 |
| Leukemia |
0 |
0.11 |
| Tobacco Use |
0 |
0.1 |
| Cataract |
0 |
0.08 |
| Diarrhea |
0 |
0.08 |
| Health Insurance |
0 |
0.08 |
| Osteoarthritis |
0 |
0.08 |
| Social Determinants of Health |
0 |
0.08 |
| Type 2 Diabetes Mellitus |
0 |
0.08 |
| A-Scan Biometry |
0 |
0.06 |
| Abuse |
0 |
0.06 |
| Birth |
0 |
0.06 |
| Chemotherapy |
0 |
0.06 |
| Child |
0 |
0.06 |
| Chronic Disease |
0 |
0.06 |
| Disease Recurrence |
0 |
0.06 |
| Face |
0 |
0.06 |
| Generics |
0 |
0.06 |
| Hand |
0 |
0.06 |
| Insurance |
0 |
0.06 |
| Kidney |
0 |
0.06 |
| Lung |
0 |
0.06 |
| Muscle |
0 |
0.06 |
| Nail |
0 |
0.06 |
| Pennsylvania |
0 |
0.06 |
| Prediabetes |
0 |
0.06 |
| Rural Health |
0 |
0.06 |
| Scan |
0 |
0.06 |
| Splenomegaly |
0 |
0.06 |
| Statistics |
0 |
0.06 |
| Tyrosine Kinase |
0 |
0.06 |
| Washington |
0 |
0.06 |
| Wisconsin |
0 |
0.06 |